UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2015
VITAE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | | 001-36617 | | 04-3567753 |
(State or Other Jurisdiction of
Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
502 West Office Center Drive Fort Washington, PA 19034 | | 19034 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (215) 461-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
At the 2015 annual meeting of stockholders (the “Annual Meeting”) of Vitae Pharmaceuticals, Inc. (the “Company”) held on May 28, 2015, the following proposals were submitted to the stockholders of the Company:
Proposal 1: | The election of one director to serve as a Class I director until the Company’s 2018 annual meeting of stockholders and until his successor is duly elected and qualified. |
| |
Proposal 2: | The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. |
For more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 15, 2015 (the “Proxy Statement”). Of the 21,829,821 shares of the Company’s common stock entitled to vote at the Annual Meeting, 15,023,172 shares, or approximately 68.81%, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below:
Proposal 1: | Election of Directors. |
The Company’s stockholders elected the following director to serve as a Class I director until the 2018 annual meeting of stockholders and until his successor is duly elected and qualified. The votes regarding the election of the director were as follows:
Director | | Votes For | | Votes Withheld | | Broker Non-Votes | |
Bryan Roberts, Ph.D. | | 12,477,907 | | 658,573 | | 1,886,692 | |
Proposal 2: | Ratification of Appointment of Ernst & Young LLP. |
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes regarding this proposal were as follows:
Votes
For | | Votes Against | | Votes Abstaining | | Broker Non-Votes | |
15,017,906 | | 3,266 | | 2,000 | | — | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VITAE PHARMACEUTICALS, INC. |
| |
| |
Date: May 29, 2015 | By: | /s/ Jeffrey S. Hatfield |
| | Jeffrey S. Hatfield |
| | Chief Executive Officer |
3
